Vaccination With Tumor mRNA in Metastatic Melanoma - Fixed Combination Versus Individual Selection of Targeted Antigens
NCT ID: NCT00204516
Last Updated: 2013-01-16
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1/PHASE2
31 participants
INTERVENTIONAL
2007-04-30
2012-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Intradermal Vaccination With Stabilized Tumor mRNA - a Clinical Phase I/II Trial in Melanoma Patients
NCT00204607
Multiepitope Peptide Vaccination in Melanoma
NCT00153569
Local Treatment of Metastatic Melanoma With Autologous Lymphocytes and the Bispecific Antibody rM28
NCT00204594
Vaccine Therapy With or Without Biological Therapy in Treating Patients With Metastatic Melanoma
NCT00006385
Vaccine Treatment for Advanced Malignant Melanoma
NCT00300612
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
mRNA Vacc
mRNA coding for melanoma associated antigens
mRNA vaccine s.c. applied weekly
GM-CSF
Given s.c. as adjuvant drug one day after vaccine
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
mRNA coding for melanoma associated antigens
mRNA vaccine s.c. applied weekly
GM-CSF
Given s.c. as adjuvant drug one day after vaccine
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* fresh frozen tumor tissue available
* informed consent given
* Karnofsky \>= 70%
Exclusion Criteria
* parallel chemotherapy
* systemic treatment with glucocorticoids
* other malignancies
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
German Research Foundation
OTHER
University Hospital Tuebingen
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Thomas Eigentler
Study Coordinator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Claus Garbe, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
University of Tuebingen, Department of Dermatology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Department of Dermatology, University of Tuebingen
Tübingen, , Germany
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RNA-Mel-03
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.